Central Line-Associated Bloodstream Infection QI Project (CLABSI)

July 31, 2026 updated by: NYU Langone Health

Central Line-Associated Bloodstream Infection (CLABSI) Quality Improvement Project

This study evaluates a daily electronic health record (EHR) alert designed to reduce unnecessary central venous catheter (CVC) use among hospitalized adults. The alert identifies patients with an active CVC and no documented indication, prompting the first-contact provider to document line necessity. The study compares alert and a secure chat intervention to usual care, with the goal of reducing unnecessary line days and related CLABSI risk.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10016
        • NYU Langone Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult inpatients with an active central venous catheter for at least 24 hours who meet alert eligibility criteria during the study period

Description

Inclusion Criteria:

  • Not hospice patient class
  • Active central line for at least 24 hours

Exclusion Criteria:

  • No active central line
  • Central line present for less than 24 hours

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Usual Care
Adult inpatients meeting eligibility criteria.
Secure Chat + Alert Cohort
Adult inpatients meeting eligibility criteria whose provider receives a daily EHR OPA alert and additional secure chat communication.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Total number of central line days without a documented indication
Time Frame: Up to Month 3
Up to Month 3

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of femoral central lines in place for more than 2 days
Time Frame: Up to Month 3
Up to Month 3
Number of non-tunneled hemodialysis catheters without an active hemodialysis or continuous renal replacement therapy order
Time Frame: Up to Month 3
Up to Month 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

NYU Langone Health

Investigators

  • Principal Investigator: Holly Krelle, NYU Langone Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

July 31, 2026

First Submitted That Met QC Criteria

July 31, 2026

First Posted (Actual)

August 5, 2026

Study Record Updates

Last Update Posted (Actual)

August 5, 2026

Last Update Submitted That Met QC Criteria

July 31, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • QI-CLABSI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made available to other researchers at this time.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe